Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
13
09
2021
accepted:
25
11
2021
pubmed:
4
12
2021
medline:
19
2
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Myocarditis and pericarditis may constitute adverse reactions of mRNA coronavirus disease 2019 (COVID-19) vaccines. This study aimed to document these reactions and to assess the association with patient sex and age. This is as an observational retrospective study using a case-non-case design (also called disproportionality study) on inflammatory heart reactions reported with mRNA COVID-19 vaccines within the World Health Organization (WHO) global safety database (VigiBase), up to June 30, 2021. Results are expressed using reporting odds ratios (RORs) and their 95% confidence interval (95% CI). Of 716,576 reports related to mRNA COVID-19 vaccines, 2,277 were cases of inflammatory heart reactions, including 1241 (55%) myocarditis and 851 (37%) pericarditis. The main age group was 18-29 years (704, 31%), and mostly male patients (1,555, 68%). Pericarditis onset was delayed compared with myocarditis with a median time to onset of 8 (3-21) vs. 3 (2-6) days, respectively (P = 0.001). Regarding myocarditis, an important disproportionate reporting was observed in adolescents (ROR, 22.3, 95% CI 19.2-25.9) and in 18-29 years old (ROR, 6.6, 95% CI 5.9-7.5) compared with older patients, as well as in male patients (ROR, 9.4, 95% CI 8.3-10.6). Reporting rate of myocarditis was increased in young adults and adolescents. Inflammatory heart reactions may rarely occur shortly following mRNA COVID-19 vaccination. Although an important disproportionate reporting of myocarditis was observed among adolescents and young adults, particularly in male patients, reporting rates support a very rare risk, that does not seem to compromise the largely positive benefit-risk balance of these vaccines. Furthermore, this study confirmed the value of disproportionality analyses for estimation of relative risks among subgroups of patients.
Identifiants
pubmed: 34860360
doi: 10.1002/cpt.2499
pmc: PMC9015432
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-613Subventions
Organisme : CIHR
Pays : Canada
Organisme : Heart & Stroke Foundation of Canada
Organisme : Genome Canada
Organisme : University of Ottawa of Heart Institute
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Br J Clin Pharmacol. 2011 Dec;72(6):905-8
pubmed: 21658092
Circulation. 2021 Aug 10;144(6):506-508
pubmed: 34133884
MMWR Morb Mortal Wkly Rep. 2021 Jul 09;70(27):977-982
pubmed: 34237049
Heart Rhythm. 2020 Sep;17(9):1463-1471
pubmed: 32387246
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
BMC Cancer. 2021 Jan 7;21(1):38
pubmed: 33413213
Circ Heart Fail. 2020 Nov;13(11):e007405
pubmed: 33176455
JAMA. 2021 Sep 28;326(12):1210-1212
pubmed: 34347001
J Am Coll Cardiol. 2004 Jul 7;44(1):201-5
pubmed: 15234435
Therapie. 2019 Apr;74(2):225-232
pubmed: 30773344
JAMA Cardiol. 2021 Sep 1;6(9):1078-1087
pubmed: 34042947
Int J Cardiol. 2018 Dec 15;273:183-186
pubmed: 30236504
JACC Cardiovasc Imaging. 2021 Nov;14(11):2155-2166
pubmed: 33975819
Intern Emerg Med. 2021 Aug;16(5):1123-1129
pubmed: 33484452
N Engl J Med. 2021 Sep 16;385(12):1138-1140
pubmed: 34432973
Am J Emerg Med. 2021 Dec;50:815.e1-815.e2
pubmed: 34229940
Arch Cardiovasc Dis. 2021 Jun-Jul;114(6-7):515-517
pubmed: 34246566
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1053-1058
pubmed: 34351881
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206
pubmed: 34185045
JAMA. 2005 Dec 7;294(21):2734-43
pubmed: 16333009
J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):180-185
pubmed: 33587399
Therapie. 2021 Jul-Aug;76(4):365-367
pubmed: 33858693
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Vaccine. 2021 Jan 29;39(5):839-845
pubmed: 33422381
Nature. 2020 Dec;588(7838):388-390
pubmed: 33324005
Nat Rev Immunol. 2015 Feb;15(2):117-29
pubmed: 25614321
Vaccines (Basel). 2021 Jan 04;9(1):
pubmed: 33406694
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Circulation. 2021 Aug 10;144(6):471-484
pubmed: 34281357
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
N Engl J Med. 2021 Sep 30;385(14):1332-1334
pubmed: 34407340
Vaccine. 2021 Jun 23;39(28):3666-3677
pubmed: 34088506
Anaesth Crit Care Pain Med. 2020 Dec;39(6):883-885
pubmed: 33130015
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1305-1309
pubmed: 32941415
JAMA Cardiol. 2021 Oct 1;6(10):1117-1118
pubmed: 34185044
JAMA Intern Med. 2021 Sep 1;181(9):1243-1245
pubmed: 33904857
Semin Immunopathol. 2019 Mar;41(2):239-249
pubmed: 30547182
Vaccine. 2021 Jun 29;39(29):3790-3793
pubmed: 34092429
N Engl J Med. 2021 May 27;384(21):2014-2027
pubmed: 34042389
Lancet. 2000 Oct 7;356(9237):1255-9
pubmed: 11072960
JAMA. 2021 Mar 16;325(11):1101-1102
pubmed: 33576785
J Clin Epidemiol. 2021 Jun;134:14-21
pubmed: 33508405
NPJ Vaccines. 2020 Feb 4;5:11
pubmed: 32047656
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246